Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) Phase 3 clinical trial of Gemcitabine and Cisplatin (GC) plus bevacizumab (B) or placebo (P)
      Google Scholar   
Citation:
J Clin Oncol vol 40 (16_suppl) 4562-4562
Meeting Instance:
ASCO 2022
Year:
2022
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
Yes
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Genentech  
Grants:
U10CA180821, U10CA180882, CA160312, U24CA196171  
Corr. Author:
 
Authors:
                                   
Networks:
LAPS-NY016   
Study
CALGB-90601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: